Acorda Therapeutics Investor Relations Material

Acorda Therapeutics, Inc. is a biopharmaceutical company that develops and commercializes therapies for neurological disorders in the United States. The company's lead product is Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS). It also develops ARCUS product for the treatment of acute migraines; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. Acorda Therapeutics' other collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics was incorporated in 1995 and is headquartered in Ardsley, New York.